Orchestra BioMed Holdings (OBIO) Return on Sales (2022 - 2025)
Historic Return on Sales for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to 24.19%.
- Orchestra BioMed Holdings' Return on Sales fell 85600.0% to 24.19% in Q3 2025 from the same period last year, while for Sep 2025 it was 26.65%, marking a year-over-year decrease of 54300.0%. This contributed to the annual value of 23.1% for FY2024, which is 58400.0% down from last year.
- According to the latest figures from Q3 2025, Orchestra BioMed Holdings' Return on Sales is 24.19%, which was down 85600.0% from 23.16% recorded in Q2 2025.
- In the past 5 years, Orchestra BioMed Holdings' Return on Sales registered a high of 5.92% during Q1 2022, and its lowest value of 63.85% during Q4 2024.
- For the 4-year period, Orchestra BioMed Holdings' Return on Sales averaged around 22.2%, with its median value being 20.51% (2024).
- Per our database at Business Quant, Orchestra BioMed Holdings' Return on Sales tumbled by -345000bps in 2023 and then soared by 168500bps in 2024.
- Quarter analysis of 4 years shows Orchestra BioMed Holdings' Return on Sales stood at 8.91% in 2022, then tumbled by -387bps to 43.41% in 2023, then crashed by -47bps to 63.85% in 2024, then surged by 62bps to 24.19% in 2025.
- Its Return on Sales stands at 24.19% for Q3 2025, versus 23.16% for Q2 2025 and 21.61% for Q1 2025.